EFFECTIVENESS AND COST OF INTEGRATING A PROTOCOL WITH USE OF LIRAGLUTIDE 3.0 MG INTO AN OBESITY SERVICE: (STRIVE Study)

Trial Profile

EFFECTIVENESS AND COST OF INTEGRATING A PROTOCOL WITH USE OF LIRAGLUTIDE 3.0 MG INTO AN OBESITY SERVICE: (STRIVE Study)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Jun 2018

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Acronyms STRIVE
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 14 Jun 2018 Planned number of patients changed from 400 to 375.
    • 14 Jun 2018 Status changed from withdrawn prior to enrolment to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top